Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone

详细信息    查看全文

• 作者：Juan Du ; Zhengang Yuan ; Chunyang Zhang ; Weijun Fu ; Hua Jiang ; Baoan Chen ; Jian Hou
• 关键词：Multiple myeloma ; TNF-α ; Polymorphism ; Thalidomide ; Dexamethasone ; Clinical outcome
• 刊名：Leukemia Research
• 出版年：2010
• 出版时间：November 2010
• 年：2010
• 卷：34
• 期：11
• 页码：1453-1458
• 全文大小：211 K

文摘

The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal + Dex) regimen. MM patients carrying the GA genotype (P = 0.01) or GA + AA genotypes (P = 0.02) at the TNF-α −308 polymorphism were associated with a reduced risk for MM. The TNF-α −238 GA + AA genotypes were associated with a significant enhancement in the progression-free survival (PFS) (P = 0.009) and a better overall survival (OS) (P = 0.088).